DE102010063788A1 - Hair treatment agent with surfactant (s) and cationic keratin hydrolyzate (s) - Google Patents

Abstract

The invention relates to hair treatment compositions which contain certain surfactant (s) and cationic keratin hydrolyzate (s) and the use of these compositions for reducing split ends.

Description

The invention relates to hair treatment compositions containing certain surfactant (s) and cationic keratin hydrolyzate (s) and to the use of these hair splitting reduction agents. Keratin fiber care products affect the natural structure and properties of hair. Thus, for example, after such treatments, the wet and dry combability of the hair, the hold and the fullness of the hair can be optimized or the hair can be protected from increased split ends. It has therefore long been customary to subject the hair to a special aftertreatment. In this case, the hair is treated with special active ingredients, for example quaternary ammonium salts or special polymers, usually in the form of a rinse. Depending on the formulation, this treatment improves the combability, the hold and the fullness of the hair and reduces the split rate.

However, the known active ingredients can not cover all needs sufficiently. Thus, although it is mentioned in the data sheets of cationic keratin hydrolysates such as Croquat WKP that this rustoff significantly improves the softening, combability and shine of hair when it is used in hair treatment compositions in a concentration of at least 0.5% by weight. However, there is no reference to the properties for the reduction of split ends. There is therefore still a need for active ingredients or combinations of active substances for cosmetic products with good care properties and good biodegradability. Especially in surfactant- and / or electrolyte-containing formulations, there is a need for additional skin care ingredients that can be easily incorporated into known formulations and are not weakened in their action due to incompatibilities with other ingredients. This is especially true in the so-called 2 in 1 products. In these, cleaning and care are combined into one step. However, a major disadvantage of these products is that care is often not taken to the necessary extent. Thus, the separate application of a shampoo and a hair cure, although time-consuming, but still leads to a much better result. This is especially true for the split behavior of hair.

It has now been found that particularly advantageous results in the prevention and treatment of split ends are achieved when incorporating certain surfactant (s) and cationic keratin hydrolyzate (s) into hair treatment compositions.

• a) mindestens ein Tensid
• b) mindestens 0,01 bis 0,5 Gew.-% eines kationischen Keratinhydrolysates der Formel (I) R'-X-R'' (I), in der
• – W für einen geradkettigen oder verzweigten, gesättigten oder ungesätttigten Kohlenwasserstoffrest mit 11 bis 24 Kohlenstoffatomen steht,
• – R'' ein Protein, ein Peptid oder ein Proteinhydrolysat bedeutet,
• – X für -C(O)O- oder -N⁺(R^III ₂)R^IV- oder -N(R^III)R^IV- oder -C(O)-N(R^V)R^VI- steht,
• – R^III -(CH₂)_x-CH₃ mit x = 0–22 bedeutet und
• – R^IV -CH₂-CH(OH)-CH₂- oder -(CH₂)_x- mit x = 0–22 bedeutet;
• – R^V und R^V unabhängig voneinander für -H oder -(CH₂)_x-CH₃ mit x = 0–22 stehen;

mit der Maßgabe, dass R'' für Keratin oder ein Keratinhydrolysat steht.A first object of the present invention is therefore the use of hair treatment compositions for the prevention and / or treatment of hair splitting, containing

• a) at least one surfactant
• b) at least 0.01 to 0.5% by weight of a cationic keratin hydrolyzate of the formula (I) R'-X-R '' (I), in the
• W is a straight-chain or branched, saturated or unsaturated hydrocarbon radical having 11 to 24 carbon atoms,
• R "denotes a protein, a peptide or a protein hydrolyzate,
• X is -C (O) O- or -N ⁺ (R ^III ₂ ) R ^IV - or -N (R ^III ) R ^IV - or -C (O) -N (R ^V ) R ^VI -,
• R ^{III is} - (CH ₂ ) _x -CH ₃ where x = 0-22 and
• - R ^{IV is} -CH ₂ -CH (OH) -CH ₂ - or - (CH ₂ ) _x - where x = 0-22;
• R ^V and R ^V independently of one another are -H or - (CH ₂ ) _x -CH ₃ with x = 0-22;

with the proviso that R "stands for keratin or a keratin hydrolyzate.

Hair treatment compositions for the purposes of the present invention are, for example, hair shampoos, hair conditioners, conditioning shampoos, hairsprays, hair conditioners, hair treatments, hair wraps, hair tonics, perming solutions, hair dye shampoos, hair dyes, hair fixatives, hair dressings, hairstyling preparations, hair lotions, mousses, hair gels , Hair waxes or their combinations. In view of the fact that men often shy away from the use of several different agents and / or several application steps, agents according to the invention are preferably those agents which the man uses anyway. Preferred agents according to the invention are therefore shampoos, conditioners or hair tonics. The agents according to the invention contain as the first essential ingredient at least one surfactant, surfactants depending on the field of application being referred to as surfactants or as emulsifiers and being selected from anionic, cationic, zwitterionic, ampholytic and nonionic surfactants and emulsifiers.

Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.5 to 70% by weight, preferably from 1 to 60% by weight and in particular from 5 to 25% by weight of anionic and / or nonionic (s) and / or cationic and / or amphoteric surfactant (s).

• – lineare und verzweigte Fettsäuren mit 8 bis 30 C-Atomen (Seifen),
• – Ethercarbonsäuren der Formel R-O-(CH₂-CH₂O)_x-CH₂-COOH, in der R eine lineare Alkylgruppe mit 8 bis 30 C-Atomen und x = 0 oder 1 bis 16 ist,
• – Acylsarcoside mit 8 bis 24 C-Atomen in der Acylgruppe,
• – Acyltauride mit 8 bis 24 C-Atomen in der Acylgruppe,
• – Acylisethionate mit 8 bis 24 C-Atomen in der Acylgruppe,
• – lineare Alkansulfonate mit 8 bis 24 C-Atomen,
• – lineare Alpha-Olefinsulfonate mit 8 bis 24 C-Atomen,
• – Alpha-Sulfofettsäuremethylester von Fettsäuren mit 8 bis 30 C-Atomen,
• – Acylglutamate der Formel (I),
  
  in der R¹CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0, 1, 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alkanolammonium oder Glucammonium steht, beispielsweise Acylglutamate, die sich von Fettsäuren mit 6 bis 22, vorzugsweise 12 bis 18 Kohlenstoffatomen ableiten, wie beispielsweise C_12/14- bzw. C_12/18-Kokosfettsäure, Laurinsäure, Myristinsäure, Palmitinsäure und/oder Stearinsäure, insbesondere Natrium-N-cocoyl- und Natrium-N-stearoyl-L-glutamat,
• – Ester einer hydroxysubstituierten Di- oder Tricarbonsäure der allgemeinen Formel (II),
  
  in der X = H oder eine -CH₂COOR-Gruppe ist, Y = H oder -OH ist unter der Bedingung, dass Y = H ist, wenn X=-CH₂COOR ist, R, R¹ und R² unabhängig voneinander ein Wasserstoffatom, ein Alkali- oder Erdalkalimetallkation, eine Ammoniumgruppe, das Kation einer ammonium-organischen Base oder einen Rest Z bedeuten, der von einer polyhydroxylierten organischen Verbindung stammt, die aus der Gruppe der veretherten (C₅-C₁₈)-Alkylpolysaccharide mit 1 bis 6 monomeren Saccharideinheiten und/oder der veretherten aliphatischen (C₆-C₁₆)-Hydroxyalkylpolyole mit 2 bis 16 Hydroxylresten ausgewählt sind, unter der Maßgabe, dass wenigstens eine der Gruppen R, R¹ oder R² ein Rest Z ist,
• – Ester der Sulfobernsteinsäure oder der Sulfosuccinate der allgemeinen Formel (III),
  
  in der M^(n+/n) für n = 1 ein Wasserstoffatom, ein Alkalimetallkation, eine Ammoniumgruppe oder das Kation einer ammonium-organischen Base und für n = 2 ein Erdalkalimetallkation darstellt und R¹ und R² unabhängig voneinander ein Wasserstoffatom, ein Alkali- oder Erdalkalimetallkation, eine Ammoniumgruppe, das Kation einer ammonium-organischen Base oder einen Rest Z bedeuten, der von einer polyhydroxylierten organischen Verbindung stammt, die aus der Gruppe der veretherten (C₆-C₁₈)-Alkylpolysaccharide mit 1 bis 6 monomeren
• – Saccharideinheiten und/oder der veretherten aliphatischen (C₆-C₁₆)-Hydroxyalkylpolyole mit 2 bis 16 Hydroxylresten ausgewählt ist, unter der Maßgabe, dass wenigstens eine der Gruppen R¹ oder R² ein Rest Z ist,
• – Sulfobernsteinsäuremono- und -dialkylester mit 8 bis 24 C-Atomen in der Alkylgruppe und Sulfobernsteinsäuremonoalkylpolyoxyethylester mit 8 bis 24 C-Atomen in der Alkylgruppe und 1 bis 6 Oxyethylgruppen,
• – Alkylsulfate und Alkylpolyglycolethersulfate der Formel R-(O-CH₂-CH₂)_x-OSO₃H, in der R eine bevorzugt lineare Alkylgruppe mit 8 bis 30 C-Atomen und x = 0 oder 1–12 ist,
• – gemischte oberflächenaktive Hydroxysulfonate gemäß DE-A-37 25 030 ,
• – Ester der Weinsäure und Zitronensäure mit Alkoholen, die Anlagerungsprodukte von etwa 2–15 Molekülen Ethylenoxid und/oder Propylenoxid an C_8-22-Fettalkohole darstellen,
• – Alkyl- und/oder Alkenyletherphosphate,
• – sulfatierte Fettsäurealkylenglycolester,
• – Monoglyceridsulfate und Monoglyceridethersulfate.

Suitable anionic surfactants and emulsifiers for the compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. As a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups and hydroxyl groups may be present in the molecule. Examples of suitable anionic surfactants and emulsifiers are, in each case in the form of the sodium, potassium and ammonium as well as the mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group,

• - linear and branched fatty acids with 8 to 30 carbon atoms (soaps),
• Ether carboxylic acids of the formula RO- (CH ₂ -CH ₂ O) _x -CH ₂ -COOH, in which R is a linear alkyl group having 8 to 30 C atoms and x = 0 or 1 to 16,
• Acylsarcosides having 8 to 24 C atoms in the acyl group,
• Acyltaurides having 8 to 24 carbon atoms in the acyl group,
• Acyl isethionates having 8 to 24 C atoms in the acyl group,
• - linear alkanesulfonates having 8 to 24 carbon atoms,
• - linear alpha-olefin sulfonates having 8 to 24 carbon atoms,
• Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 C atoms,
• Acylglutamates of the formula (I),
  
  in which R ¹ CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium, for example acylglutamates, which are derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as, for example, C _12/14 or C _12/18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid, in particular sodium N-cocoyl and sodium N-stearoyl-L-glutamate,
• Esters of a hydroxy-substituted di- or tricarboxylic acid of the general formula (II),
  
  wherein X is H or a -CH ₂ COOR group, Y is H or -OH is under the condition that Y is H when X is -CH ₂ COOR, R, R ¹ and R ^{2 are} independently a hydrogen atom, an alkali or alkaline earth metal cation, an ammonium group, the cation of an ammonium-organic base or a radical Z, that of a polyhydroxylated organic compound selected from the group consisting of the etherified (C ₅ -C ₁₈ ) -alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C ₆ -C ₁₆ ) -hydroxyalkylpolyols having 2 to 16 hydroxyl groups, among which In that at least one of the groups R, R ¹ or R ^{2 is} a radical Z,
• Esters of sulfosuccinic acid or sulfosuccinates of general formula (III),
  
  in which M ^{(n + / n)} for n = 1 represents a hydrogen atom, an alkali metal cation, an ammonium group or the cation of an ammonium organic base and for n = 2 an alkaline earth metal cation and R ¹ and R ² independently of one another represent a hydrogen atom, an alkali metal cation or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C ₆ -C ₁₈ ) alkyl polysaccharides having 1 to 6 monomers
• Saccharide units and / or the etherified aliphatic (C ₆ -C ₁₆ ) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R ¹ or R ^{2 is} a radical Z,
• Sulfosuccinic acid mono- and dialkyl esters having 8 to 24 C atoms in the alkyl group and sulfosuccinic acid monoalkylpolyoxyethyl esters having 8 to 24 C atoms in the alkyl group and 1 to 6 oxyethyl groups,
• Alkyl sulfates and alkyl polyglycol ether sulfates of the formula R- (O-CH ₂ -CH ₂ ) _x -OSO ₃ H, in which R is a preferably linear alkyl group having 8 to 30 C atoms and x = 0 or 1-12,
• Mixed hydroxysulfonates according to DE-A-37 25 030 .
• Esters of tartaric acid and citric acid with alcohols which are adducts of about 2-15 molecules of ethylene oxide and / or propylene oxide with C _8-22 fatty alcohols,
• Alkyl and / or alkenyl ether phosphates,
• - sulfated fatty acid alkylene glycol esters,
• Monoglyceride sulfates and monoglyceride ether sulfates.

Preferred anionic surfactants and emulsifiers are acylglutamates, acyl isethionates, acyl sarcosinates and acyl taurates, each with a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds, which in particularly preferred embodiments of an octanoyl, decanoyl, lauroyl , Myristoyl, palmitoyl and stearoyl radical, esters of tartaric acid, citric acid or succinic acid or of the salts of these acids with alkylated glucose, in particular the products with the INCI name Disodium Coco-Glucoside Citrate, Sodium Coco-Glucoside Tartrate and Disodium Coco-glucosides sulfosuccinates, alkyl polyglycol ether sulfates and ether carboxylic acids having 8 to 18 carbon atoms in the alkyl group and up to 12 ethoxy groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl ester having 8 to 18 carbon atoms in the alkyl group and 1 to 6 ethoxy groups.

Zwitterionic surfactants and emulsifiers are those surface-active compounds which carry in the molecule at least one quaternary ammonium group and at least one - COO ^(-) or -SO ₃ ^(-) group. Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl 3-Hydroxyethylimidazolines having in each case 8 to 18 C atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.

Further preferred anionic surfactants are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acid salts having from 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule and sulfosuccinic acid mono- and dialkyl esters having from 8 to 18 carbon atoms in the alkyl group and sulfosuccinic acid monoalkyl polyoxyethyl esters having from 8 to 18 C atoms in the alkyl group and 1 to 6 oxyethyl groups.

Particularly preferred anionic surfactants are the alkali metal or ammonium salts of lauryl ether sulfate having a degree of ethoxylation of 2 to 4 EO.

Particularly preferred hair treatment compositions according to the invention are characterized in that they contain, based on their weight, from 0.1 to 20% by weight, preferably from 0.25 to 17.5% by weight and in particular from 5 to 15% by weight of anionic (s ) Surfactant (s), more preferably fatty alcohol ether sulfates of the formula H ₃ C- (CH ₂ ) _n - (OCH ₂ CH ₂ ) _k -OSO ₃ ^- M ⁺ in which n represents values of from 5 to 21, preferably from 7 to 19, more preferably from 9 to 17 and in particular from 11 to 13 and k for values of 1, 2, 3, 4, 5, 6, 7, 8 , 9 or 10, preferably 1, 2 or 3 and especially 2, and M is a cation from the group Na ⁺ , K ⁺ NH ₄ ⁺ , ½Mg ²⁺ , ½Zn ²⁺ , preferably Na ⁺ .

Zwitterionic surfactants and emulsifiers are surface-active compounds which carry at least one quaternary ammonium group and at least one - COO ^(-) or SO ₃ ^(-) group in the molecule. Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines such as the N-alkyl-N, N-dimethylammoniumglycinate, for example the Kokosalkyldimethylammoniumglycinat, N-acyl-aminopropyl-N, N-dimethylammoniumglycinate, for example Kokosacylaminopropyldimethylammoniumglycinat, and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazoline each having 8 to 18 carbon atoms in the alkyl or acyl group and cocoacylaminoethylhydroxyethylcarboxymethylglycinat. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.

Ampholytic surfactants and emulsifiers are understood to mean those surface-active compounds which, apart from a C ₈ -C ₂₄ -alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SO ₃ H group and are capable of forming internal salts , Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C Atoms in the alkyl group. Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C ₁₂ -C ₁₈ acylsarcosine.

Particularly preferred hair treatment compositions according to the invention are characterized in that they contain amphoteric surfactant (s) from the groups of N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids each having about 8 to 24 carbon atoms in the alkyl group, alkylaminoacetic acids each having about 8 to 24 carbon atoms in the alkyl group, N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionates, C ₁₂ -C ₁₈ -acylsarcosine, N- Alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines having in each case 8 to 18 C Atoms in the alkyl or acyl group, Kokosacylaminoethylhydroxyethylcarboxymethylglycinat, the known under the INCI name cocamidopropyl betaine Ver compounds containing compounds known under the INCI name Disodium Cocoamphodiacetate, preferred agents comprising the amphoteric surfactant (s) in amounts of from 0.5 to 9% by weight, preferably from 0.75 to 8% by weight .-% and in particular from 1 to 7.5 wt .-%, each based on the total agent included.

in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen steht.Particularly preferred hair treatment compositions contain as amphoteric surfactants betaines of the formula (VI)

in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.

These surfactants are referred to the INCI nomenclature as Amidopropylbetaine, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamidopropylbetaine. According to the invention, particular preference is given to using surfactants of the formula (VI) which are a mixture of the following representatives:
H ₃ C- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₉ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₁₁ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₁₃ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₁₅ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₇ -CH = CH- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-

Particular preference is given to using surfactants of the formula (VI) within narrower ranges of amounts. Here, agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (VI).

enthalten, in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen steht.In addition to the amphoteric surfactant (s) of the formula (VI) or in its place, the hair-treatment compositions according to the invention may be used with particular preference as amphoteric surfactants betaines of the formula (VII)

in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.

These surfactants are referred to according to the INCI nomenclature as amphoacetates, wherein the representatives derived from coconut fatty acids are preferred and are referred to as cocoamphoactetates.

in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen und M für ein Kation steht. Diese Tenside werden nach der INCI-Nomenklatur als Amphodiacetate bezeichnet, wobei die Vertreter, die sich von Kokosfettsäuren ableiten, bevorzugt sind und als Cocoamphodiactetate bezeichnet werden.For reasons of production technology, surfactants of this type always also contain betaines of the formula (VIIa)

in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms and M is a cation. These surfactants are referred to according to the INCI nomenclature as Amphodiacetate, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamphodiactetate.

According to the invention, particular preference is given to using surfactants of the formula (VII) which are a mixture of the following representatives:
H ₃ C- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^-
H 3 C- (CH ₂ ) ₉ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^-
H ₃ C- (CH _{2) 11} -C (O) -NH- (CH _{2) 2} NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₁₃ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₁₅ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₇ -CH = CH- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^-

Particular preference is given to using surfactants of the formula (VII) within narrower ranges of amounts. Here, agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (VII).

Particularly preferred nonionic surfactants are alkyl polyglycosides. Accordingly, hair treatment compositions according to the invention are preferred which contain as nonionic surfactants - based on their weight - 0.1 to 20 wt .-% alkylpolyglycosides of the general formula RO- (Z) _x , where R is alkyl, Z for sugar and x for the number the sugar units stands.

According to the invention, preference is given to using alkylpolyglycosides corresponding to the general formula RO - (Z) _x , where R is alkyl, Z is sugar and x is the number of sugar units.

• – im wesentlichen aus C₈- und C₁₀-Alkylgruppen,
• – im wesentlichen aus C₁₂- und C₁₄-Alkylgruppen,
• – im wesentlichen aus C₈- bis C₁₆-Alkylgruppen oder
• – im wesentlichen aus C₁₂- bis C₁₆-Alkylgruppen oder
• – im wesentlichen aus C₁₆ bis C₁₈-Alkylgruppen besteht.

Particular preference is given to those alkylpolyglycosides in which R

• Consisting essentially of C ₈ and C ₁₀ -alkyl groups,
• Essentially of C ₁₂ and C ₁₄ alkyl groups,
• - Essentially from C ₈ - to C ₁₆ alkyl groups or
• - Essentially from C ₁₂ - to C ₁₆ alkyl groups or
• - Consists essentially of C ₁₆ to C ₁₈ alkyl groups.

As sugar building block Z it is possible to use any desired mono- or oligosaccharides. Usually, sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used. Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.

The alkylpolyglycosides which can be used according to the invention contain on average from 1.1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1.1 to 1.8.

beschreiben, in der R-CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0 und/oder 1, 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alkanolammonium oder Glucammonium steht. Verkaufsprodukte sind beispielsweise von der Hoechst AG, Frankfurt/DE oder der Ajinomoto Co. Inc., Tokyo/JP erhältlich.Other surfactants which can be used particularly advantageously in the compositions according to the invention, especially in admixture with alkylpolyglycosides, are glutamates, asparaginates and sulfoacetates. Here, hair treatment compositions according to the invention are preferred which contain, based on their weight, 0.1 to 20% by weight of fatty acid glutamates (acylglutamates) and / or fatty acid asparaginates (acylasparaginates) and / or alkylsulfoacetates (sulfoacetic acid alkyl esters). Acylglutamate can be defined by the formula

in which R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium , For example, sales products are from the Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP available.

Typical examples of suitable acylglutamates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C12 / 14 or C12 / 18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particularly preferred are sodium N-cocoyl and sodium N-stearoyl-L-glutamate.

The compositions according to the invention may contain the alkyl and / or alkenyl oligoglucosides and the acyl glutamates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50.

beschreiben, in der R-CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0 und/oder 1, 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alkanolammonium oder Glucammonium steht. Verkaufsprodukte sind beispielsweise von der Hoechst AG, Frankfurt/DE oder der Ajinomoto Co. Inc., Tokyo/JP erhältlich.Acylasparaginates can be defined by the formula

in which R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium , For example, sales products are from the Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP available.

Typical examples of suitable acylasparaginates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18, carbon atoms, such as, for example, C12 / 14 or C12 / 18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particularly preferred are sodium N-cocoyl and sodium N-stearoyl-L-aspartate.

The agents according to the invention may also contain the alkyl and / or alkenyl oligoglucosides and the acylasparaginates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50.

Sulfoacetates (sulfoacetic acid esters), are usually salts of esters of sulfoacetic acid and can be represented by the general formula ROC (O) -CH ₂ -SO ₂ -OX in which R is a linear or branched alkyl or alkenyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium stands. Particularly preferred is the use of the sodium salt of sulfoacetic acid with the INCI name: sodium lauryl sulfoacetate): H ₃ C- (CH ₂ ) ₁₁ -O-CO-CH ₂ -SO ₂ -ONa Sodium lauryl sulphoacetate is a white, free-flowing powder which reacts neutrally, with good foaming power, wetting power and dispersibility.

Usable according to the invention are cationic surfactants of the quaternary ammonium compound type, as described below. Esterquats according to the formula (Tkat1-2) form the first group.

• – ein verzweigter oder unverzweigter Alkylrest mit 1 bis 4 Kohlenstoffatomen, welcher mindestens eine Hydroxylgruppe enthalten kann, oder
• – ein gesättigter oder ungesättigter, verzweigter oder unverzweigter oder ein cyclischer gesättigter oder ungesättigter Alkylrest mit 6 bis 30 Kohlenstoffatomen, welcher mindestens eine Hydroxylgruppe enthalten kann, oder
• – ein Aryl oder Alkarylrest, beispielsweise Phenyl oder Benzyl,
• – den Rest (-X-R4), mit der Maßgabe, dass höchstens 2 der Reste R1, R2 oder R3 für diesen Rest stehen können:

Here, the radicals R1, R2 and R3 are each independently and may be the same or different. The radicals R1, R2 and R3 mean:

• A branched or unbranched alkyl radical having 1 to 4 carbon atoms which may contain at least one hydroxyl group, or
• A saturated or unsaturated, branched or unbranched or cyclic saturated or unsaturated alkyl radical having from 6 to 30 carbon atoms which may contain at least one hydroxyl group, or
• An aryl or alkaryl radical, for example phenyl or benzyl,
• - the radical (-X-R4), with the proviso that at most 2 of the radicals R1, R2 or R3 can stand for this radical:

The rest - (X-R4) is contained at least 1 to 3 times.

• 1) -(CH2)n- mit n = 1 bis 20, vorzugsweise n = 1 bis 10 und besonders bevorzugt n = 1–5, oder
• 2) -(CH2-CHR5-O)n- mit n = 1 bis 200, vorzugsweise 1 bis 100, besonders bevorzugt 1 bis 50, und besonders bevorzugt 1 bis 20 mit R5 in der Bedeutung von Wasserstoff, Methyl oder Ethyl,
• 3) eine Hydroxyalkylgruppe mit ein bis vier Kohlenstoffatomen, welche verzweigt oder unverzweigt sein kann, und welche mindestens eine und höchstens 3 Hydroxygruppen enthält. Beispiele sind: -CH₂OH, -CH₂CH₂OH, -CHOHCHOH, -CH₂CHOHCH₃, -CH(CH₂OH)₂, -COH(CH₂OH)₂, -CH₂CHOHCH₂OH, -CH₂CH₂CH₂OH und Hydroxybutylreste,

und R4 steht für:

• 1) R6-O-CO-, worin R6 einen gesättigten oder ungesättigten, verzweigten oder unverzweigten oder einen cyclischen gesättigten oder ungesättigten Alkylrest mit 6 bis 30 Kohlenstoffatomen ist, welcher mindestens eine Hydroxygruppe enthalten kann, und welcher gegebenenfalls weiterhin mit 1 bis 100 Ethylenoxideinheiten und/oder 1 bis 100 Propylenoxideinheiten oxethyliert sein kann, oder
• 2) R7-CO-, worin R7 einen gesättigten oder ungesättigten, verzweigten oder unverzweigten oder einen cyclischen gesättigten oder ungesättigten Alkylrest mit 6 bis 30 Kohlenstoffatomen ist, welcher mindestens eine Hydroxygruppe enthalten kann, und welcher gegebenenfalls weiterhin mit 1 bis 100 Ethylenoxideinheiten und/oder 1 bis 100 Propylenoxideinheiten oxethyliert sein kann,

und A steht für ein physiologisch verträgliches organisches oder anorganisches Anion und wird an dieser Stelle stellvertretend für alle auch im folgenden beschriebenen Strukturen definiert. Das Anion aller beschriebenen kationischen Verbindungen ist ausgewählt aus den Halogenidionen, Fluorid, Chlorid, Bromid, Iodid, Sulfaten der allgemeinen Formel RSO₃ ^–, worin R die Bedeutung von gesättigtem oder ungesättigtem Alkylresten mit 1 bis 4 Kohlenstoffatomen hat, oder anionischen Reste organischer Säuren wie Maleat, Fumarat, Oxalat, Tartrat, Citrat, Lactat oder Acetat. Solche Produkte werden beispielsweise unter den Warenzeichen Rewoquat^®, Stepantex^®, Dehyquart^®, Armocare^® und Akypoquat^® vertrieben. Die Produkte Armocare^® VGH-70, Dehyquart^® F-75, Dehyquart^®C-4046, Dehyquart^® L80, Dehyquart^® F-30, Dehyquart^® AU-35, Rewoquat^® WE18, Rewoquat^® WE38 DPG, Stepantex^® VS 90 und Akypoquat^® 131 sind Beispiele für diese Esterquats.Where X stands for:

• 1) - (CH 2) n - with n = 1 to 20, preferably n = 1 to 10 and particularly preferably n = 1-5, or
• 2) - (CH 2 -CHR 5 -O) n - where n = 1 to 200, preferably 1 to 100, particularly preferably 1 to 50, and particularly preferably 1 to 20 with R 5 in the meaning of hydrogen, methyl or ethyl,
• 3) a hydroxyalkyl group of one to four carbon atoms, which may be branched or unbranched, and which contains at least one and at most 3 hydroxy groups. Examples are: -CH ₂ OH, -CH ₂ CH ₂ OH, -CHOHCHOH, -CH ₂ CHOHCH ₃ , -CH (CH ₂ OH) ₂ , -COH (CH ₂ OH) ₂ , -CH ₂ CHOHCH ₂ OH, CH ₂ CH ₂ CH ₂ OH and hydroxybutyl radicals,

and R4 stands for:

• 1) R 6 -O-CO-, wherein R 6 is a saturated or unsaturated, branched or unbranched or cyclic saturated or unsaturated alkyl radical having 6 to 30 carbon atoms, which may contain at least one hydroxy group, and which optionally further with 1 to 100 ethylene oxide units and or 1 to 100 propylene oxide units may be ethoxylated, or
• 2) R7-CO-, wherein R7 is a saturated or unsaturated, branched or unbranched or cyclic saturated or unsaturated alkyl radical having 6 to 30 carbon atoms, which may contain at least one hydroxy group, and which optionally further with 1 to 100 ethylene oxide units and / or 1 to 100 propylene oxide units can be ethoxylated,

and A is a physiologically acceptable organic or inorganic anion and is defined here as representative of all structures also described below. The anion of all described cationic compounds is selected from the halide ions, fluoride, chloride, bromide, iodide, sulfates of the general formula RSO ₃ ^- , in which R has the meaning of saturated or unsaturated alkyl radicals having 1 to 4 carbon atoms, or anionic radicals of organic acids such as maleate, fumarate, Oxalate, tartrate, citrate, lactate or acetate. Such products are marketed under the trademarks Rewoquat ^®, Stepantex® ^®, Dehyquart® ^{®, ®} and Armocare® Akypoquat ^®. The products Armocare ^® VGH-70, Dehyquart ^® F-75, Dehyquart ^® C-4046, Dehyquart ^® L80, Dehyquart ^® F-30, Dehyquart ^® AU-35, Rewoquat ^® WE18, Rewoquat ^® WE38 DPG, Stepantex ^® VS 90 and Akypoquat ^® 131 are examples of these esterquats.

Further compounds of the formula (Tkat1-2) which are particularly preferred according to the invention belong to the formula (Tkat1-2.1), the cationic betaine esters.

R8 corresponds in its meaning R7.

Particularly preferred are the esterquats with tradenames Armocare ^® VGH-70 are, as well as Dehyquart ^® F-75, Dehyquart ^® L80, Stepantex ^® VS 90 and Akypoquat ^® 131st

Another group are quaternary imidazoline compounds. The formula (Tkat2) shown below shows the structure of these compounds.

The radicals R independently of one another each represent a saturated or unsaturated, linear or branched hydrocarbon radical having a chain length of 8 to 30 carbon atoms. The preferred compounds of the formula (Tkat2) contain for R the same hydrocarbon radical. The chain length of the radicals R is preferably 12 to 21 carbon atoms. A stands for an anion as previously described. Particularly examples according to the invention are obtainable, for example, under the INCII names Quaternium-27, Quaternium-72, Quaternium-83 and Quaternium-91. Quaternium-91 is most preferred according to the invention.

• 1) Wasserstoff oder
• 2) ein Alkylrest mit 1 bis 4 C-Atomen, welcher gleich oder verschieden, gesättigt oder ungesättigt sein kann, und
• 3) eine verzweigte oder unverzweigte Hydroxyalkylgruppe mit ein bis 4 Kohlenstoffatomen mit mindestens einer und höchstens drei Hydroxygruppen beispielsweise -CH₂OH, -CH₂CH₂OH, -CHOHCHOH, -CH₂CHOHCH₃, -CH(CH₂OH)₂, -COH(CH₂OH)₂, -CH₂CHOHCH₂OH, -CH₂CH₂CH₂OH und Hydroxybutylreste, und

A ein Anion wie zuvor beschrieben und
n eine ganze Zahl zwischen 1 und 10 bedeuten.In a particularly preferred embodiment of the invention, the compositions according to the invention furthermore comprise at least one amine and / or cationized amine, in particular an amidoamine and / or a cationized amidoamine having the following structural formulas: R1-NH- (CH _{2) n} -N ⁺ R ² R ³ R ⁴ A (Tkat3) in which R 1 is an acyl or alkyl radical having 6 to 30 C atoms which is branched or unbranched,
may be saturated or unsaturated, and wherein the acyl radical and / or the alkyl radical may contain at least one OH group, and
R2, R3 and R4 are each independently

• 1) hydrogen or
• 2) an alkyl radical having 1 to 4 C atoms, which may be identical or different, saturated or unsaturated, and
• 3) a branched or unbranched hydroxyalkyl group having one to 4 carbon atoms having at least one and at most three hydroxy groups, for example -CH ₂ OH, -CH ₂ CH ₂ OH, -CHOHCHOH, -CH ₂ CHOHCH ₃ , -CH (CH ₂ OH) ₂ , -COH (CH ₂ OH) ₂ , -CH ₂ CHOHCH ₂ OH, -CH ₂ CH ₂ CH ₂ OH and hydroxybutyl radicals, and

A is an anion as previously described and
n is an integer between 1 and 10.

Preference is given to a composition in which the amine and / or the quaternized amine according to general formulas (Tkat3) is an amidoamine and / or a quaternized amidoamine, in which R1 is a branched or unbranched, saturated or unsaturated acyl radical having 6 to 30 C atoms, which may contain at least one OH group means. Preference is given here to a fatty acid radical of oils and waxes, in particular of natural oils and waxes. Examples of these are lanolin, bees or candellila waxes.

Also preferred are those amidoamines and / or quaternized amidoamines in which R 2, R 3 and / or R 4 in the formula (Tkat3) represent a radical according to the general formula CH ₂ CH ₂ OR 5, where R 5 is the meaning of alkyl radicals having 1 to 4 carbon atoms , Hydroxyethyl or hydrogen. The preferred size of n in the general formula (Tkat8) is an integer between 2 and 5.

The alkylamidoamines can both be present as such and converted by protonation in a correspondingly acidic solution into a quaternary compound in the composition. According to the invention, the cationic alkylamidoamines are preferred.

Examples of such inventive commercial products are Witcamine ^® 100, Incromine ^® BB, Mackine ^® 401 and other Mackine ^® grades, Adogen ^® S18V, and as a permanent cationic aminoamines: Rewoquat ^® RTM 50, Empigen ^® CSC, Swanol ^® Lanoquat DES-50, Rewoquat ^® UTM 50, Schercoquat® ^® BAS ^® Lexquat AMG-BEO, or Incroquat ^® behenyl HE.

Furthermore, alkyltrimethylammonium chlorides having preferably 10 to 18 carbon atoms in the alkyl radical and / or dialkyldimethylammonium chlorides having preferably 10 to 18 carbon atoms in the alkyl radical and / or trialkylmethylammonium chlorides having preferably 10 to 18 carbon atoms in the alkyl radical and / or cetyltrimethylammonium chloride and / or stearyltrimethylammonium chloride and / or distearyldimethylammonium chloride and / or Lauryldimethylammoniumchlorid and / or Lauryldimethylbenzylammoniumchlorid and / or Tricetylmethylammoniumchlorid be used

The aforementioned cationic surfactants may be used individually or in any combination with each other, wherein amounts between 0.01 to 10 wt .-%, preferably in amounts of 0.01 to 7.5 wt .-%, and most preferably in amounts of 0.1 to 5.0 wt .-% included. The very best results are obtained with amounts of from 0.1 to 3.0% by weight, based in each case on the total composition of the particular agent.

• – R' für einen geradkettigen oder verzweigten, gesättigten oder ungesätttigten Kohlenwasserstoffrest mit 11 bis 24 Kohlenstoffatomen steht,
• – R'' ein Protein, ein Peptid oder ein Hydrolysat aus Keratin bedeutet,
• – X für -C(O)O- oder -N⁺(R^III ₂)R^IV- oder -N(R^III)R^IV- oder -C(O)-N(R^V)R^VI- steht,
• – R^III -(CH₂)_x-CH₃ mit x = 0–22 bedeutet und
• – R^IV -CH₂-CH(OH)-CH₂- oder -(CH₂)_x- mit x = 0–22 bedeutet;
• – R^V und R^V unabhängig voneinander für -H oder -(CH₂)_x-CH₃ mit x = 0–22 stehen.

As a second essential ingredient, the agents according to the invention contain at least one proteolipid of the formula (I) R'-X-R '' (I), in the

• R 'is a straight-chain or branched, saturated or unsaturated hydrocarbon radical having 11 to 24 carbon atoms,
• R '' means a protein, a peptide or a hydrolyzate of keratin,
• X is -C (O) O- or -N ⁺ (R ^III ₂ ) R ^IV - or -N (R ^III ) R ^IV - or -C (O) -N (R ^V ) R ^VI -,
• R ^{III is} - (CH ₂ ) _x -CH ₃ where x = 0-22 and
• - R ^{IV is} -CH ₂ -CH (OH) -CH ₂ - or - (CH ₂ ) _x - where x = 0-22;
• - R ^V and R ^V independently of one another are -H or - (CH ₂ ) _x -CH ₃ with x = 0-22.

Preferably, the cationic Keratinhydrolysate be used within certain amounts in the inventive compositions. Preferred hair treatment compositions according to the invention contain - based on their weight - from 0.01 to 0.5 wt .-%, preferably 0.02 to 0.5 wt .-%, particularly preferably 0.05 to 0.5 wt .-%, further preferably 0.1 to 0.5 wt .-% and in particular 0.1 to 0.35 wt .-% cationic Keratinhydrolysate.

The radical R "in formula (I) represents a peptide or a protein or a protein hydrolyzate, each based on keratin.

The molecular weight of the cationic keratin hydrolyzate contained in the agents according to the invention is from 500 to 10,000 Da, preferably from 750 to 5000 Da, more preferably from 750 to 2000 Da and in particular from 800 to 1500 Da.

It is preferred if the radical R "of the cationic keratin hydrolysates used in the agents according to the invention contains no methionine. It is further preferred if the radical R "of the cationic keratin hydrolysates used in the agents according to the invention contains large amounts of cysteine and / or cystine.

An example of an inventive commercial product is Croquat ^® WKP. Another product of the invention is available as a commercial product Promois® ^® WK-HCAQ. The most preferred product carries the INCI name Cocodimonium Hydroxypropyl Hydrolyzed Keratin.

Protein hydrolysates are product mixtures obtained by acid, alkaline or enzymatically catalyzed degradation of proteins (proteins). According to the invention, protein hydrolysates of both vegetable and animal origin can be used.

Animal protein hydrolysates are, for example, elastin, collagen, keratin, silk and milk protein protein hydrolysates, which may also be present in the form of salts. Such products are, for example, under the trademarks Dehylan ^® (Cognis), Promois® ^® (Interorgana) Collapuron ^® (Cognis), Nutrilan® ^® (Cognis), Gelita-Sol ^® (German Gelatinefabriken Stoess & Co), Lexein ^® (Inolex) and kerasol tm ^® (Croda) sold.

Preferred according to the invention is the use of protein hydrolysates of plant origin, eg. Soybean, almond, rice, pea, potato and wheat protein hydrolysates. Such products are, for example, under the trademarks Gluadin ^® (Cognis), diamine ^® (Diamalt) ^® (Inolex) and Crotein ^® (Croda) available.

Preferably, regardless of the choice of X in formula (I), the R '' group is selected from keratin or keratin hydrolysates. Preferred hair treatment compositions according to the invention are characterized in that they comprise at least one cationic keratin hydrolyzate of the formula (I) in which R "represents keratin or a keratin hydrolyzate.

Particularly preferred groupings RX- are in the tables of the Priotitätsschrift DE 102009048299.7 listed. This is expressly and fully incorporated by reference. The groupings disclosed therein are bound in further preferred embodiments of the present invention to keratin or keratin hydrolyzate as group R ".

Irrespective of the choice of the grouping -X- in formula (I), hair treatment compositions according to the invention which contain at least one cationic keratin hydrolyzate of the formula (I) in which R ^{III is} -CH ₃ and R ^{IV is} - (CH ₂ ) _x - with x = 0, 1, 2, 3, 4, 5, 6, 7, 8 stands. Furthermore, particularly preferred hair treatment compositions according to the invention are characterized in that they contain at least one cationic keratin hydrolyzate of the formula (I) in which X is -N ⁺ (CH ₃ ) ₂ -CH ₂ -CH (OH) -CH ₂ - and R 'is - (CH ₂ ) ₁₇ -CH ₃ .

It has proved to be advantageous, in addition to the cationic keratin hydrolyzate (s) used according to the invention, to use protein hydrolysates as the third ingredient. These enhance the action of cationic keratin hydrolysates and, in turn, increase their effects. The protein hydrolysates were described in detail above as R ''. In summary, preference is given to hair treatment compositions according to the invention which additionally comprise, based on their weight, from 0.01 to 10% by weight, preferably from 0.05 to 7% by weight, particularly preferably from 0.1 to 5% by weight, more preferably 0 , 25 to 2.5 wt .-% and in particular 0.5 to 2.0 wt .-% protein hydrolyzate (s), preferably keratin hydrolyzate (s).

• i. L-Carnitin und/oder seiner Salze;
• ii. Panthenol und/oder Panthothensäure;
• iii. der 2-Furanone und/oder deren Derivate, insbesondere Pantolacton;
• iv. Taurin und/oder seiner Salze;
• v. Niacinamid;
• vi. Ubichinon
• vii. Ectoin;
• viii. Allantoin.

The care effects of the compositions according to the invention can be further enhanced by using certain care substances. These are preferably selected from certain groups of known care substances, since these care substances harmonize perfectly with the proteolipids employed in accordance with the formulation and the care effect. According to preferred hair treatment compositions are characterized in that they additionally care substance (s) - based on their weight - in amounts of 0.001 to 10 wt .-%, preferably 0.005 to 7.5 wt .-%, particularly preferably 0.01 to 5 wt % and in particular 0.05 to 2.5 wt .-%, with preferred care substance (s) are selected from the group

• i. L-carnitine and / or its salts;
• ii. Panthenol and / or panthothenic acid;
• iii. the 2-furanones and / or their derivatives, in particular pantolactone;
• iv. Taurine and / or its salts;
• v. niacinamide;
• vi. ubiquinone
• vii. Ectoin;
• viii. Allantoin.

In hair treatment compositions according to the invention of this embodiment, the surfactant / cationic Keratinhydrolysat combination is combined with at least one care substance which is selected from L-carnitine and / or its salts, panthenol and / or pantothenic acid, 2-furanones and / or derivatives thereof, in particular pantolactone , Taurine and / or its salts, niacinamide, ubiquinones, ectoine, allantoin. These conditioners are described below. As the betaine, L-carnitine can form addition compounds and double salts. L-carnitine derivatives which are preferred according to the invention are selected in particular from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and particularly preferably L-carnitine tartrate. The L-carnitine compounds mentioned are available, for example, from Lonza GmbH (Wuppertal, Germany).

Preferred hair treatment compositions according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.005 to 7.5% by weight, particularly preferably from 0.01 to 5% by weight and in particular 0.05 contain up to 2.5 wt .-% L-carnitine or L-carnitine derivatives, with preferred L-carnitine derivatives are selected from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate.

Panthenol (IUPAC name: (+) - (R) -2,4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethylbutyramide) is converted to pantothenic acid in the body. Pantothenic acid is a vitamin from the group of B vitamins (vitamin B5).

Preferred hair treatment compositions according to the invention are characterized in that they contain, based on their weight, from 0.01 to 5% by weight, preferably from 0.05 to 2.5% by weight, particularly preferably from 0.1 to 1.5% by weight. % and in particular 0.25 to 1 wt .-% of panthenol ((±) -2,4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethyl-butyramide).

According to the invention preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7 , 5 wt .-% and in particular 0.5 to 5 wt .-% of at least one of the following furanone derivatives: (R) - (-) - 4-hydroxymethyl-yrol-butyrolactone and / or D, L-4-hydroxymethyl-γ -butyrolactone and / or (S) - (+) - 4-hydroxymethyl-γ-butyrolactone and / or R - (-) - 2-hydroxy-3,3-dimethyl-γ-butyrolactone and / or D, L-2 -Hydroxy-3,3-dimethyl-γ-butyrolactone and / or S (+) - 2-hydroxy-3,3-dimethyl-γ-butyrolactone and / or 4-hydroxy-2,5-dimethyl-3 (2H) -furanone and / or tetrahydro-5-oxo-2-furancarboxylic acid and / or tetrahydro-5-oxo-2-furancarboxylic acid, Na salt and / or tetrahydro-5-oxo-2-furancarboxylic acid, K salt and / or 2 , 5-Dihydro-5-methoxy-2-furanone and / or dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone. Further Furanone go from the German priority font DE 102009048299.7 which is fully referenced in content.

In a very particularly preferred embodiment of the teaching according to the invention, the compound used is dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone (pantolactone).

Another, more preferably usable care substance which has activating properties is taurine. According to the invention preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7 , 5 wt .-% and in particular 0.5 to 5 wt .-% taurine (2-aminoethanesulfonic acid).

Another preferred group of care agents in the invention. Means are vitamins, provitamins or vitamin precursors. These are described below:
The group of substances called vitamin A includes retinol (vitamin A ₁ ) and 3,4-didehydroretinol (vitamin A ₂ ). The β-carotene is the provitamin of retinol. As vitamin A component according to the invention, for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration. The agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.

• – Vitamin B₁ (Thiamin)
• – Vitamin B₂ (Riboflavin)
• – Vitamin B₃. Unter dieser Bezeichnung werden häufig die Verbindungen Nicotinsäure und Nicotinsäureamid (Niacinamid) geführt. Erfindungsgemäß bevorzugt ist das Nicotinsäureamid, das in den erfindungsgemäß verwendeten Mitteln bevorzugt in Mengen von 0,05 bis 1 Gew.-%, bezogen auf das gesamte Mittel, enthalten ist.
• – Vitamin B₅ (Pantothensäure, Panthenol und Pantolacton). Im Rahmen dieser Gruppe wird bevorzugt das Panthenol und/oder Pantolacton eingesetzt (siehe weiter unten). Erfindungsgemäß einsetzbare Derivate des Panthenols sind insbesondere die Ester und Ether des Panthenols sowie kationisch derivatisierte Panthenole. Einzelne Vertreter sind beispielsweise das Panthenoltriacetat, der Panthenolmonoethylether und dessen Monoacetat sowie die in der WO 92/13829 offenbarten kationischen Panthenolderivate. Die genannten Verbindungen des Vitamin B₅-Typs sind in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,05–10 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0,1–5 Gew.-% sind besonders bevorzugt.
• – Vitamin B₆ (Pyridoxin sowie Pyridoxamin und Pyridoxal).

The vitamin B group or the vitamin B complex include, among others

• - Vitamin B ₁ (thiamine)
• - Vitamin B ₂ (riboflavin)
• - Vitamin B ₃ . Under this name, the compounds nicotinic acid and nicotinamide (niacinamide) are often performed. Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
• - Vitamin B ₅ (pantothenic acid, panthenol and pantolactone). Panthenol and / or pantolactone are preferably used in the context of this group (see below). Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are for example the Panthenoltriacetat, the Panthenolmonoethylether and its monoacetate as well as in the WO 92/13829 disclosed cationic panthenol derivatives. The said compounds of the vitamin B ₅ type are preferably present in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
• - Vitamin B ₆ (pyridoxine and pyridoxamine and pyridoxal).

Vitamin C (ascorbic acid). Vitamin C is used in the agents according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.

Vitamin E (tocopherols, especially α-tocopherol). Tocopherol and its derivatives, which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.

Vitamin F. The term "vitamin F" is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.

Vitamin H. Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-d] -imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile become established. Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.

In summary, hair-treatment compositions according to the invention are preferred which, based on their weight, are 0.1 to 5% by weight, preferably 0.2 to 4% by weight, more preferably 0.25 to 3.5% by weight, more preferably Contain 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors, preferably the groups A, B, C, E, F and H. preferred 2,4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethyl-butyramide, provitamin B ₅ ) and / or pantothenic acid (vitamin B ₃ , vitamin B ₅ ) and / or niacin , Niacinamide or nicotinamide (vitamin B ₃ ) and / or L-ascorbic acid (vitamin C) and / or thiamine (vitamin B ₁ ) and / or riboflavin (vitamin B ₂ , vitamin G) and / or biotin (vitamin B ₇ , Vitamin H) and / or folic acid (vitamin B ₉ , vitamin B _c or vitamin M) and / or vitamin B ₆ and / or vitamin B ₁₂ .

enthalten in der
X, Y, Z stehen unabhängig voneinander für -O- oder -NH- oder NR⁴- oder eine chemische Bindung
R¹, R², R³ stehen unabhängig voneinander für ein Wasserstoffatom oder eine gegebenenfalls substituierte Arylgruppe oder eine gegebenenfalls substituierte (C₁-C₆)-Alkylgruppe oder eine Hydroxyalkylgruppe oder eine Polyhydroxyalkylgruppe oder eine gegebenenfalls substituierte (C₁-C₆)-Alkylengruppe, oder einen (C₁-C₆)-Acylrest, wobei bevorzugte Reste unabhängig voneinander ausgewählt sind aus -H, -CH₃, -CH₂CH₃, -(CH₂)₂CH₂, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃
R⁴ steht für -CH₃, -CH₂CH₃, -(CH₂)₂CH₂, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃
n steht für Werte von 1 bis 20, vorzugsweise von 2 bis 15 und insbesondere für 5, 6, 7, 8, 9, 10.It has been shown that certain quinones have a special suitability as a care substance. As a further care substance, the compositions according to the invention can therefore contain from 0.0001 to 5% by weight of at least one biochinone of the formula (Ubi)

contained in the
X, Y, Z are independently -O- or -NH- or NR ⁴ - or a chemical bond
R ¹ , R ² , R ³ independently of one another represent a hydrogen atom or an optionally substituted aryl group or an optionally substituted (C ₁ -C ₆ ) -alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (C ₁ -C ₆ ) - Alkylene group, or a (C ₁ -C ₆ ) -acyl radical, preferred radicals being selected independently of one another from -H, -CH ₃ , -CH ₂ CH ₃ , - (CH ₂ ) ₂ CH ₂ , -CH (CH ₃ ) ₂ , - (CH ₂ ) ₃ CH ₃ , -CH (CH ₃ ) CH ₂ CH ₃ , -CH ₂ CH (CH ₃ ) ₂ , -C (CH ₃ ) ₃
R ⁴ is -CH ₃ , -CH ₂ CH ₃ , - (CH ₂ ) ₂ CH ₂ , -CH (CH ₃ ) ₂ , - (CH ₂ ) ₃ CH ₃ , -CH (CH ₃ ) CH ₂ CH ₃ , -CH ₂ CH (CH ₃ ) ₂ , -C (CH ₃ ) ₃
n stands for values from 1 to 20, preferably from 2 to 15 and in particular for 5, 6, 7, 8, 9, 10.

in der n für die Werte = 6, 7, 8, 9 oder 10, besonders bevorzugt für 10 (Coenzym Q10) steht. Alternativ zu den besonders bevorzugten Ubichinonen oder zusätzlich zu ihnen können die erfindungsgemäßen Mittel auch Plastochinone enthalten. Hier sind bevorzugte erfindungsgemäße Mittel dadurch gekennzeichnet, dass sie 0,0002 bis 4 Gew.-%, vorzugsweise 0,0005 bis 3 Gew.-%, besonders bevorzugt 0,001 bis 2 Gew.-%, weiter bevorzugt 0,0015 bis 1 und insbesondere 0,002 bis 0,5 Gew.-% mindestens eines Plastochinons der Formel (Ubi-b) enthalten

in der n für Werte von 1 bis 20, vorzugsweise von 2 bis 15 und insbesondere für 5, 6, 7, 8, 9, 10 steht, wobei besonders bevorzugte Mittel Plastochinon PQ-9 enthalten.Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as care substance based on their weight - 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0.1 wt .-% containing at least one ubiquinone and / or at least one ubiquinol and / or at least one derivative of these substances, preferred agents containing a ubiquinone of the formula (Ubi)

in which n stands for the values = 6, 7, 8, 9 or 10, particularly preferably 10 (coenzyme Q10). As an alternative to the particularly preferred ubiquinones or in addition to them, the agents according to the invention may also contain plastoquinones. Here, preferred agents according to the invention are characterized in that they are 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% of at least one plastoquinone of the formula (Ubi-b)

in which n is from 1 to 20, preferably from 2 to 15 and in particular from 5, 6, 7, 8, 9, 10, with particularly preferred agents containing plastoquinone PQ-9.

As a further care enhancer, the agents according to the invention may contain ectoin. Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0 , 1 to 1% by weight of (S) -2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (ectoine) and the physiologically tolerated salts of this compound and / or (S, S) -5- Hydroxy-2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (hydroxyectoine) and the physiologically acceptable salts of this compound.

Another conditioner is allantoin. According to the invention, particularly preferred hair treatment compositions contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0.1 to 1 5% ureidohydantoin (allantoin).

To improve the elasticity and strengthen the internal structure of the hair treated with the agents according to the invention, the compositions according to the invention may contain purine and / or purine derivatives as a care substance. In particular, the combination of purine and / or purine derivatives with ubiquinones and / or plastoquinones as a care substance means that the hairs treated with appropriate agents show, inter alia, higher measured values in differential thermal analysis and improved wet and dry combabilities.

Among purine, the purines and the purine derivatives, some representatives are particularly preferred according to the invention. According to preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s), the following compounds being preferred: purine, adenine, guanine, uric acid, hypoxanthine, 6-purinethiol, 6-thioguanine, xanthine , Caffeine, theobromine, theophylline.

It is also advantageous to use purine or purine derivatives and biochinones in a certain ratio to each other. Here, agents according to the invention are preferred in which the weight ratio of purine (derivative (s)) and biochinone (s) 10: 1 to 1: 100, preferably 5: 1 to 1:50, particularly preferably 2: 1 to 1:20 and especially 1: 1 to 1:10.

As already mentioned, caffeine is a particularly preferred purine derivative, and coenzyme Q10 is a particularly preferred biochinone. Particularly preferred agents according to the invention are therefore characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular 0.01 to 0.1 wt .-% caffeine and 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% coenzyme Q10 included.

As a conditioner, the compositions of the invention may also contain flavonoids. There are well over 6500 different flavonoids known, which can be divided into flavonols, flavones, flavanones, isoflavonoids and anthocyanins.

According to the invention flavonoids from all six groups can be used, with certain representatives from the individual groups are preferred as a care substance because of their particularly intense action. Preferred flavonols are quercetin, rutin, kaempferol, myricetin, isorhamnetin, preferred flavanols are catechin, gallocatechin, epicatechin, epigallocatechin gallate, theaflavin, thearubigin, preferred flavones are luteolin, apigenin, morin, preferred flavanones are hesperetin, naringenin, eriodictyol, preferred isoflavonoids are genistein , Daidzein, and preferred anthocyanidins (anthocyanins) are cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin.

According to the invention particularly preferred hair treatment compositions are characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0.1% by weight of flavonoids, in particular flavonols, more preferably 3,3 ', 4', 5,7-pentahydroxyflavone (quercetin) and / or 3,3 ', 4', 5,7-pentahydroxyflavone -3-O-rutinoside (rutin), included.

Preference is also the use of bisabolol and / or bisabololoxides as a care substance in the inventive compositions. Here, hair treatment compositions according to the invention are preferred which additionally contain 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1.5 wt % Bisabolol and / or oxides of bisabolol, preferably (-) - alpha-bisabolol.

Creatine is also suitable as a care substance according to the invention. Particularly preferred hair treatment compositions according to the invention contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7.5 wt .-% and in particular 0.5 to 5 wt .-% N-methyl-guanidino-acetic acid (creatine).

The compositions according to the invention may contain, in addition to the ingredients mentioned above and optional further ingredients, other substances which prevent, alleviate or cure hair loss. In particular, a content of hair root stabilizing agents is advantageous. These substances are described below:
Propecia (finasteride) is currently the only product approved worldwide that has been proven efficacy and tolerability in numerous studies. Propecia causes less DHT to be produced from testosterone.

Minoxidil is probably the oldest proven hair restorer with or without supplemental additives. There are hair lotions containing 2% -5% minoxidil, as well as gels with up to 15% minoxidil.

To combat the hormonal effects on hair follicles, spironolactone in the form of hair tonic and in combination with minoxidil can be used for external application. Spironolactones act as androgen receptor blockers, ie the binding of DHT to the hair follicles is prevented.

In summary, hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of hair root stabilizing substances, in particular minoxidil and / or finasteride and / or ketoconazole.

Additional antidandruff active ingredients (for example climbazole, piroctone oil amines or zinc pyrithione) are used to purposefully reduce the amount of dandruff causing the dandruff, to restore the normal bacterial count to the normal percentage and to reduce the scaling to the physiological level. However, laboratory tests have shown that the different species representatives of Pityrosporum ovale react differently to the antidandruff active ingredients. In order to maximally combat all dandruff is therefore a combination of anti-dandruff active ingredients most successful.

In summary, hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of antidandruff active ingredients, in particular piroctone olamine (1-hydroxy-4-methyl-6- (2,4,4-tri-methylpentyl) -pyridine-2 ( 1H) -one, compound with 2-aminoethanol, 1: 1) and / or zinc pyrithione and / or selenium sulfide and / or climbazole and / or salicylic acid or fumaric acid.

In addition to the care substances, the agents according to the invention may contain further care substances. Their presence is not absolutely necessary for achieving the effects according to the invention, but further effects, such as a pleasant touch or a pleasant application feel, can result from the use of these care substances.

As a further ingredient, the agents according to the invention may with particular preference contain one or more amino acids. Amino acids which can be used particularly preferably according to the invention are selected from the group glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, β Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine-sulfoxide (L-alliin), L-trans-4-hydroxyproline, L-5-oxoproline ( L-pyroglutamic acid), L-phosphoserine, creatine, 3-methyl-L-histidine, L-ornithine, whereby both the individual amino acids and mixtures can be used.

Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges. Here, preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.02 to 2.5 wt .-%, particularly preferably 0.05 to 1.5 Wt .-%, more preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group of glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.

• – Monosachhariden, insbesondere D-Ribose und/oder D-Xylose und/oder L-Arabinose und/oder D-Glucose und/oder D-Mannose und/oder D-Galactose und/oder D-Fructose und/oder Sorbose und/oder L-Fucose und/oder L-Rhamnose
• – Disacchariden, insbesondere Saccharose und/oder Maltose und/oder Lactose und/oder Trehalose und/oder Cellobiose und/oder Gentiobiose und/oder Isomaltose.

As a further component, the agents according to the invention may contain at least one carbohydrate from the group of monosaccharides, disaccharides and / or oligosaccharides. Here, preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4 wt. -%, more preferably 0.5 to 3.5 wt .-% and in particular 0.75 to 2.5 wt .-% carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides containing preferred carbohydrates are selected out

• Monosaccharides, in particular D-ribose and / or D-xylose and / or L-arabinose and / or D-glucose and / or D-mannose and / or D-galactose and / or D-fructose and / or sorbose and / or L-fucose and / or L-rhamnose
• - Disaccharides, in particular sucrose and / or maltose and / or lactose and / or trehalose and / or cellobiose and / or gentiobiose and / or isomaltose.

A particularly preferred group of ingredients are the silicones.

• (i) Polyalkylsiloxanen, Polyarylsiloxanen, Polyalkylarylsiloxanen, die flüchtig oder nicht flüchtig, geradkettig, verzweigt oder cyclisch, vernetzt oder nicht vernetzt sind;
• (ii) Polysiloxanen, die in ihrer allgemeinen Struktur eine oder mehrere organofunktionelle Gruppen enthalten, die ausgewählt sind unter:
• a) substituierten oder unsubstituierten aminierten Gruppen;
• b) (per)fluorierten Gruppen;
• c) Thiolgruppen;
• d) Carboxylatgruppen;
• e) hydroxylierten Gruppen;
• f) alkoxylierten Gruppen;
• g) Acyloxyalkylgruppen;
• h) amphoteren Gruppen;
• i) Bisulfitgruppen;
• j) Hydroxyacylaminogruppen;
• k) Carboxygruppen;
• l) Sulfonsäuregruppen; und
• m) Sulfat- oder Thiosulfatgruppen;
• (iii) linearen Polysiloxan(A)-Polyoxyalkylen(B)-Blockcopoylmeren vom Typ (A-B)_n mit n > 3;
• (iv) gepfropften Siliconpolymeren mit nicht siliconhaltigem, organischen Grundgerüst, die aus einer organischen Hauptkette bestehen, welche aus organischen Monomeren gebildet wird, die kein Silicon enthalten, auf die in der Kette sowie gegebenenfalls an mindestens einem Kettenende mindestens ein Polysiloxanmakromer gepfropft wurde;
• (v) gepfropften Siliconpolymeren mit Polysiloxan-Grundgerüst, auf das nicht siliconhaltige, organische Monomere gepfropft wurden, die eine Polysiloxan-Hauptkette aufweisen, auf die in der Kette sowie gegebenenfalls an mindestens einem ihrer Enden mindestens ein organisches Makromer gepfropft wurde, das kein Silicon enthält;

oder deren Gemischen.Preferred agents according to the invention are characterized in that they contain at least one silicone, preferably a silicone, which is selected from:

• (i) polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes which are volatile or nonvolatile, straight chain, branched or cyclic, crosslinked or uncrosslinked;
• (ii) Polysiloxanes containing in their general structure one or more organofunctional groups selected from:
• a) substituted or unsubstituted aminated groups;
• b) (per) fluorinated groups;
• c) thiol groups;
• d) carboxylate groups;
• e) hydroxylated groups;
• f) alkoxylated groups;
• g) acyloxyalkyl groups;
• h) amphoteric groups;
• i) bisulfite groups;
• j) hydroxyacylamino groups;
• k) carboxy groups;
• l) sulfonic acid groups; and
• m) sulphate or thiosulphate groups;
• (iii) linear polysiloxane (A) polyoxyalkylene (B) block copolymers of the (AB) _{n type} with n>3;
• (iv) grafted silicone polymers having a non-silicone organic backbone consisting of an organic backbone formed from organic monomers containing no silicone grafted with at least one polysiloxane macromer in the chain and optionally at least one chain end;
• (v) grafted polysiloxane backbone silicone polymers having grafted thereto non-silicone organic monomers having a polysiloxane backbone to which at least one organic macromer not containing silicone has been grafted in the chain, and optionally at least at one of its ends ;

or their mixtures.

Particularly preferred compositions according to the invention comprise the silicone (s) preferably in amounts of from 0.1 to 10% by weight, preferably from 0.25 to 7% by weight and in particular from 0.5 to 5% by weight. , in each case based on the total mean.

Preferred silicones are described below.

Particularly preferred agents according to the invention are characterized in that they contain at least one silicone of the formula Si-I (CH ₃ ) ₃ Si- [O-Si (CH ₃ ) ₂ P] _x -O-Si (CH ₃ ) ₃ (Si-I), in which x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.

These silicones are called DIMETHICONE according to the INCI nomenclature.

Preferred silicones which can be used according to the invention have viscosities of from 0.2 to 2 mm ² s ^-1 at 20 ° C., silicones having viscosities of from 0.5 to 1 mm ² s ^{-1 being} particularly preferred.

Particularly preferred agents according to the invention contain one or more amino-functional silicones. Such silicones may, for. B. by the formula M (R _a Q _b SiO _{(4-ab) / 2) x} (R _c SiO _{(4-c) / 2) y} M wherein R in the above formula is a hydrocarbon or a hydrocarbon group of 1 to about 6 carbon atoms, Q is a polar group of the general formula -R ¹ HZ wherein R ^{1 is} a divalent linking group attached to hydrogen and the group Z is an organic, amino-functional radical containing at least one amino-functional group, carbon and hydrogen atoms, carbon, hydrogen and oxygen atoms or carbon, hydrogen and nitrogen atoms; "A" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 1 to about 3, "a" + "b" is less than or equal to 3, and "c" is a number in the range about From 1 to about 3, and x is a number ranging from 1 to about 2,000, preferably from about 3 to about 50, and most preferably from about 3 to about 25, and y is a number ranging from about 20 to about 10,000, preferably from about 125 to about 10,000, and most preferably from about 150 to about 1,000, and M is a suitable silicone end group as known in the art, preferably trimethylsiloxy. Non-limiting examples of the groups represented by R include alkyl groups such as methyl, ethyl, propyl, isopropyl, isopropyl, butyl, isobutyl, amyl, isoamyl, hexyl, isohexyl and the like; Alkenyl radicals such as vinyl, halovinyl, alkylvinyl, allyl, haloallyl, alkylallyl; Cycloalkyl radicals such as cyclobutyl, cyclopentyl, cyclohexyl and the like; Phenyl radicals, benzyl radicals, halohydrocarbon radicals such as 3-chloropropyl, 4-bromobutyl, 3,3,3-trifluoropropyl, chlorocyclohexyl, bromophenyl, chlorophenyl and the like, and sulfur-containing radicals such as mercaptoethyl, mercaptopropyl, mercaptohexyl, mercaptophenyl and the like; preferably R is an alkyl radical containing from 1 to about 6 carbon atoms, and most preferably R is methyl. Examples of R ¹ include methylene, ethylene, propylene, hexamethylene, decamethylene, -CH ₂ CH (CH ₃ ) CH ₂ -, phenylene, naphthylene, -CH ₂ CH ₂ SCH ₂ CH ₂ -, -CH ₂ CH ₂ OCH ₂ - , -OCH ₂ CH ₂ -, -OCH ₂ CH ₂ CH ₂ -, -CH ₂ CH (CH ₃ ) C (O) OCH ₂ -, - (CH ₂ ) ₃ CC (O) OCH ₂ CH ₂ -, C ₆ H ₄ C ₆ H ₄ -, -C ₆ H ₄ CH ₂ C ₆ H ₄ -; and - (CH ₂ P) ₃ C (O) SCH ₂ CH ₂ -.

Z is an organic, amino-functional radical containing at least one functional amino group. A possible formula for Z is NH (CH ₂ ) _z NH ₂ , wherein z is 1 or more. Another possible formula for Z is -NH (CH _{2) z} (CH _{2) zz} NH wherein both z and zz independently 1 or more, this structure includes diamino-ring structures such as piperazinyl. Z is most preferably a -NHCH ₂ CH ₂ NH ₂ radical. Another possible formula for Z is -N (OH ₂ ) _Z (CH ₂ ) _zz NX ₂ or -NX ₂ , wherein each X of X _{2 is} independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz is 0. Q is most preferably a polar, amine functional group of the formula -CH ₂ CH ₂ CH ₂ NHCH ₂ CH ₂ NH ₂ . In the formulas, "a" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 2 to about 3, "a" + "b" is less than or equal to 3, and "c "Is a number in the range of about 1 to about 3. The molar ratio of the R _a Q _b SiO _{(4-ab) / 2} units to the R _c SiO _{(4-c) / 2} units is in the range of about 1: 2 to 1:65, preferably from about 1: 5 to about 1:65, and most preferably from about 1:15 to about 1:20. When one or more silicones of the above formula are used, the various variable substituents in the above formula may be different for the various silicone components present in the silicone blend.

enthalten, worin m und n Zahlen sind, deren Summe (m + n) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei n vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt.Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si-IIa)

in which m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10 assumes.

enthalten, worin R für -OH, -O-CH₃ oder eine -CH₃-Gruppe steht und m, n1 und n2 Zahlen sind, deren Summe (m + n1 + n2) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei die Summe (n1 + n2) vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt.These silicones are referred to as trimethylsilylamodimethicones according to the INCI declaration. Also particularly preferred are agents according to the invention which are an amino-functional silicone of the formula (Si-IIb)

in which R is -OH, -O-CH ₃ or a -CH ₃ group and m, n1 and n2 are numbers whose sum (m + n1 + n2) is between 1 and 2,000, preferably between 50 and 150 , where the sum (n1 + n2) preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10.

These silicones are referred to as amodimethicones according to the INCI declaration.

Agents preferred according to the invention are characterized in that they contain, based on their weight, 0.01 to 10 wt .-%, preferably 0.1 to 8 wt .-%, particularly preferably 0.25 to 7.5 wt .-% and in particular from 0.5 to 5% by weight of amino-functional silicone (s).

enthalten, in der x für eine Zahl von 3 bis 200, vorzugsweise von 3 bis 10, weiter bevorzugt von 30 bis 7 und insbesondere 3, 4, 5 oder 6, steht.The INCI CYCLOMETHICONE designated cyclic dimethicones are inventively used with preference. Here, agents according to the invention are preferred which contain at least one silicone of the formula Si-III

in which x is a number from 3 to 200, preferably from 3 to 10, more preferably from 30 to 7 and in particular 3, 4, 5 or 6.

Agents which are likewise preferred according to the invention are characterized in that they contain at least one silicone of the formula Si-IV R ₃ Si [O-SiR ₂ ] _x - (CH ₂ ) _n - [O-SiR ₂ ] _y -O-SiR ₃ (Si-IV), in which R is identical or different radicals from the group -H, -phenyl, -benzyl, -CH ₂ -CH (CH ₃ ) Ph, the C _1-20 -alkyl radicals, preferably -CH ₃ , -CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH ₂ CH ₂ H ₃ , -CH ₂ CH (CH ₃ ) ₂ , -CH (CH ₃ ) CH ₂ CH ₃ , - C (CH ₃ ) ₃ , x and y are a number from 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and especially 0, 1, 2, 3, 4, 5 or 6, stand and n is a number from 0 to 10, preferably from 1 to 8 and in particular from 2, 3, 4, 5, 6.

The silicones are preferably water-soluble. Agents preferred according to the invention are characterized in that they contain at least one water-soluble silicone.

Furthermore, in a preferred embodiment of the invention, an agent according to the invention may also contain UV filters (I). The UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum lies in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC (<280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.

The UV filters used according to the invention can be selected, for example, from substituted benzophenones, p-aminobenzoic acid esters, diphenylacrylic acid esters, cinnamic acid esters, salicylic acid esters, benzimidazoles and o-aminobenzoic acid esters. Preference is given to those UV filters whose molar extinction coefficient at the absorption maximum is above 15,000, in particular above 20,000.

Furthermore, it has been found that in structurally similar UV filters in many cases, the water-insoluble compound in the teaching of the invention has the higher effect compared to such water-soluble compounds that differ from it by one or more additional ionic groups. In the context of the invention, water-insoluble are to be understood as meaning those UV filters which dissolve in water at 20 ° C. to not more than 1% by weight, in particular not more than 0.1% by weight. Furthermore, these compounds should be soluble in the usual cosmetic oil components at room temperature to at least 0.1, in particular at least 1 wt .-%). The use of water-insoluble UV filters may therefore be preferred according to the invention.

According to a further embodiment of the invention, preference is given to those UV filters which have a cationic group, in particular a quaternary ammonium group.

Two preferred UV filters with cationic groups are the commercially available compounds cinnamic acid trimethyl ammonium chloride (Incroquat ^® UV-283) and Dodecyldimethylaminobenzamidopropyl-tosylate (Escalol ^® HP 610).

Of course, the teaching of the invention also includes the use of a combination of several UV filters. In the context of this embodiment, the combination of at least one water-insoluble UV filter with at least one UV filter with a cationic group is preferred.

The UV filters are usually contained in the compositions according to the invention in amounts of 0.1-5% by weight, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred. In addition, it may prove advantageous if the compositions according to the invention contain penetration aids and / or swelling agents (M). These include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and its derivatives, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol ethers, for example propylene glycol monoethyl ether, carbonates, bicarbonates, Diols and triols, and especially 1,2-diols and 1,3-diols such as 1,2-propanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-dodecanediol, 1,3-propanediol, 1 , 6-hexanediol, 1,5-pentanediol, 1,4-butanediol. Another object of the present invention is a method for the treatment of keratinic fibers, in particular human hair, in which a hair treatment agent according to the invention applied to keratinous fibers and left there either until the next hair wash or rinsed after a contact time of 30 to 300 seconds. With respect to preferred embodiments of the method according to the invention mutatis mutandis applies to the means of the invention.

Examples:

All data in% by weight, in each case based on the total agent.

Ingredients of the examples: Proteolipid G (Keratin) -OC (O) - (CH ₂ ) ₁₀ -CH ₃ Proteolipid H (Keratin) -OC (O) - (CH ₂ ) ₁₆ -CH ₃ Proteolipid I (Keratin) -N ⁺ (CH ₃ ) ₂ - (CH ₂ ) ₁₆ -CH ₃ Proteolipid J H ₃ C- (CH ₂ ) ₁₇ -N ⁺ (CH ₃ ) ₂ -CH ₂ -CH (OH) -CH ₂ - (Keratin) Proteolipid K H ₃ C- (CH ₂ ) ₁₇ -N ⁺ (CH ₃ ) ₂ -CH ₂ -CH (OH) -CH ₂ - (Keratin) Proteolipid L (Keratin) -N ⁺ (CH ₃ ) ₂ -CH ₂ -CH (OH) -CH ₂ -Cocoyl Euperlan ^® PK3000 about 60-64% solids; INCI name: Glycol Distearate, Glycerol, Laureth-4, Cocamidopropyl Betaine (Cognis) Cetiol ^® HE Coconut monoglyceride with approx. 7.3 EO units (INCI name: PEG-7 Glyceryl Cocoate) (Cognis) Polymer ^JR® 400 quaternized hydroxyethylcellulose (INCI name: Polyquaternium-10) (Amerchol) Dehyquart® ^® F75 Fatty alcohols methyltriethanolammonium methylsulfate dialkyl ester mixture (INCI name: distearoylethyl hydroxyethylmonium methosulfate, cetearyl alcohol) (Henkel) Varisoft ^® W 575 PG INCI name: Quaternium-87 (Goldschmidt) Emulmetik ^® 100 Lecithin (Degussa) Cutina ^® CP Cetyl palmitate (Cognis) Dehyquart® ^® A-CA Trimethylhexadecylammonium chloride (about 24-26% active ingredient, INCI name: Aqua (Water), Cetrimonium Chloride) (Cognis) Gluadin® ^® W20 Wheat protein hydrolyzate (at least 20% solids, INCI name: Aqua (Water), Hydrolyzed Wheat Protein, Sodium Benzoate, Phenoxyethanol, Methylparaben, Propylparaben) (Cognis) Salcare ^® SC 96 about 50% active ingredient content; INCI name: Polyquaternium-37, Propylene Glycol Dicaprylate / Dicaprate, PPG-1 Trideceth-6 (CIBA) Synthalen ^® K Polyacrylic acid (about 89% active ingredient content, INCI name: Carbomer) (3 V Sigma) Neutrol ^® TE N, N, N ', N', - tetrakis (2-hydroxypropyl) ethylenediamine (INCI name: tetrahydroxypropyl ethylene diamine) (BASF) Luviskol ^® K30 Polyvinylpyrrolidone (100% solids, INCI name: PVP) (BASF) Gafquat ^® 755 Dimethylaminoethyl methacrylate-vinylpyrrolidone copolymer; quaternized with diethyl sulfate (about 19% solids in water, INCI name: Polyquaternium-11) (ISP) Dow Corning ^1401® Dimethylcyclosiloxane dimethylpolysiloxanol mixture (about 13% solids, INCI name: cyclomethicone, dimethiconol) (Dow coming) Sepigel ^® 305 about 45-49% solids; INCI name: polyacrylamide, C _13-14 isoparaffin, laureth-7) (Seppic) Cutina ^® GMS-V Glycerol mono / dipalmitate / stearate (INCI name: Glyceryl Stearate) (Cognis) shampoos A B C D e F Citric acid anhydrous 0.5 0.5 0.5 0.5 0.5 0.5 Natriumlaurylethersulfat.25% 50 50 50 50 50 50 Disodium Cocoamphodiacetate 7 7 7 7 7 7 salicylic acid 0.2 0.2 0.2 0.2 0.2 0.2 D-panthenol 75% 0.5 0.5 0.5 0.5 0.5 0.5 Na benzoate 0.5 0.5 0.5 0.5 0.5 0.5 Euperlan PK 3000 AM 2 2 2 2 2 2 Cetiol HE 1 1 1 1 1 1 Proteolipid G 0.2 - - - - - Proteolipid H - 0.2 - - - - Proteolipid I - - 0.2 - - - Proteolipid J - - - 0.2 - - Proteolipid K - - - - 0.2 - Proteolipid L - - - - - 0.2 Polymer JR 400 0.5 0.5 0.5 0.5 0.5 0.5 casein 1.0 1.0 1.0 1.0 1.0 1.0 Perfume 0.5 0.5 0.5 0.5 0.5 0.5 PEG-40 Hydrogenated Castor Oil 455 1 1 1 1 1 1 Macadamia nut oil, refined 0.2 0.2 0.2 0.2 0.2 0.2 Sodium chloride fine-medium 0.5 0.5 0.5 0.5 0.5 0.5 Water, demineralized ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 construction creams A B C D e F Paraffin Liquidum 1 1 1 1 1 1 Dehyquart F 75 2 2 2 2 2 2 Proteolipid G 0.2 - - - - - Proteolipid H - 0.2 - - - - Proteolipid I - - 0.2 - - - Proteolipid J - - - 0.2 - Proteolipid K - - - - 0.2 - Proteolipid L - - - - - 0.2 Varisoft W 75 PG 1.5 1.5 1.5 1.5 1.5 1.5 Cetearyl Alcohol 3.5 3.5 3.5 3.5 3.5 3.5 Emulmetic 100 0.4 0.4 0.4 0.4 0.4 0.4 Propylparaben 0.15 0.15 0.15 0.15 0.15 0.15 Cutina CP 0.7 0.7 0.7 0.7 0.7 0.7 stearamidopropyldimethylamines 1 1 1 1 1 1 Dehyquart A CA 3 3 3 3 3 3 citric acid 0.5 0.5 0.5 0.5 0.5 0.5 methylparaben 0.15 0.15 0.15 0.15 0.15 0.15 Phenoxyethanol, pure 0.4 0.4 0.4 0.4 0.4 0.4 D-panthenol 75% 0.2 0.2 0.2 0.2 0.2 0.2 Gluadin W 20 1 1 1 1 1 1 Perfume 0.4 0.4 0.4 0.4 0.4 0.4 Salcare SC 96 1 1 1 1 1 1 Water, demineralized ad 100 ad 100 ad 100 ad 100 ad 100 ad ad 100 Leave in treatments A B C D e F Synthetic K 0.25 0.25 0.25 0.25 0.25 0.25 Sepigel 305 1 1 1 1 1 1 Dehyquart F 75 0.5 0.5 0.5 0.5 0.5 0.5 Polymer JR 400 0.3 0.3 0.3 0.3 0.3 0.3 Neutrol TE 0.4 0.4 0.4 0.4 0.4 0.4 Proteolipid G 0.25 - - - - - Proteolipid H - 0.25 - - - - Proteolipid I - - 0.25 - - - Proteolipid J - - - 0.25 - - Proteolipid K - - - - 0.25 - Proteolipid L - - - - - 0.25 Perfume 0.3 0.3 0.3 0.3 0.3 0.3 D-panthenol 75% 0.5 0.5 0.5 0.5 0.5 0.5 Luviskol K 30 powder 0.5 0.5 0.5 0.5 0.5 0.5 Gafquat 755 N 0.5 0.5 0.5 0.5 0.5 0.5 Dow Corning 1401 Fluid 1 1 1 1 1 1 Ethanol 96% DEP denatured 15 15 15 15 15 15 Sea urchin 305 1.6 1.6 1.6 1.6 1.6 Water, demineralized ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 Intensive cure A B C D e F Varisoft W 75 PG 1.5 1.5 1.5 1.5 1.5 1.5 Paraffin Liquidum 1 1 1 1 1 1 Dehyquart F 75 2 2 2 2 2 2 stearamidopropyldimethylamines 1 1 1 1 1 1 Proteolipid G 0.25 - - - - - Proteolipid H - 0.25 - - - - Proteolipid I - - 0.25 - - - Proteolipid J - - - 0.25 - Proteolipid K - - - - 0.25 - Proteolipid L - - - - - 0.25 Cetearyl Alcohol 5 5 5 5 5 5 Cutina GMS-V 1 1 1 1 1 1 citric acid 0.3 0.3 0.3 0.3 0.3 0.3 Dehyquart A CA 5 5 5 5 5 5 Salcare SC 96 0.5 0.5 0.5 0.5 0.5 0.5 Perfume 0.4 0.4 0.4 0.4 0.4 0.4 D-panthenol 75% 0.5 0.5 0.5 0.5 0.5 0.5 Water, demineralized ad 100 ad 100 ad 100 ad 100 ad 100 ad 100

Proof of the reduction of split ends:

To test the reduction of split ends, hair was treated with a commercial shampoo and then a commercial conditioner. As a shampoo or conditioner, the products of the series Gliss Kur Oil Nutritive were used as a shampoo and conditioner. In contrast to the treatment with a commercially available shampoo and conditioner an amount of 0.1 wt .-% Croquat WKP ^® was added in a second test series to the shampoo Gliss Oil Nutritive and exclusively enclose the lock of hair treated further. Thereafter, the treated strands were dried and combed 20,000 times. Both strands of hair exhibited a split rate reduction of 94%. It is thus clear that commercial shampoos and a commercial conditioner are identical in their effect by a small amount of cationic keratin hydrolyzate in a shampoo. However, this can eliminate the time-consuming second step of treating hair with a conditioner without loss of effect when a composition according to the invention is used.

QUOTES INCLUDE IN THE DESCRIPTION

This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Cited patent literature

• DE 3725030 A [0007]
• DE 102009048299 [0062, 0070]
• WO 92/13829 [0074]

Cited non-patent literature

• Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP [0029]
• Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP [0032]

Claims (8)

Use of hair treatment compositions which comprise a) at least one surfactant b) at least one cationic keratin hydrolyzate of the formula (1) R'-X-R '' (I), in which - R 'is a straight-chain or branched, saturated or unsaturated hydrocarbon radical having 11 to 24 carbon atoms, - R''is a keratin or a keratin hydrolyzate, --X is -C (O) O- or -N ⁺ (R ^III ₂ ) R ^IV - or -N (R ^III ) R ^IV - or -C (O) -N (R ^V ) R ^VI -, R ^III - (CH ₂ ) _x -CH ₃ with x = 0-22 and - R ^{IV represents} -CH ₂ -CH (OH) -CH ₂ - or - (CH ₂ ), where x = 0-22; - R ^V and R ^V independently of one another are -H or - (CH ₂ ) _x -CH ₃ with x = 0-22, for reducing split ends. Use according to claim 1, characterized in that the hair treatment agent - based on its weight - 0.5 to 70 wt .-%, preferably 1 to 60 wt .-% and in particular 5 to 25 wt .-% of anionic (s) and / or nonionic and / or cationic and / or amphoteric surfactant (s). Use according to one of claims 1 or 2, characterized in that the hair treatment agent contains 0.01 to 10 wt .-%, of at least one cationic surfactant. Use according to any one of claims 1 to 3, characterized in that the hair styling agent contains - based on its weight 0.01 to 0.5 wt .-% cationic Keratinhydrolysate. Use according to any one of Claims 1 to 4, characterized in that the hair treatment composition contains at least one cationic protein hydrolyzate of the formula (I) in which X represents -N ⁺ (CH ₃ ) ₂ -CH ₂ -CH (OH) -CH ₂ - and R 'is - (CH ₂ ) ₁₇ -CH ₃ . Use according to any one of Claims 1 to 5, characterized in that the hair treatment composition contains at least one cationic keratin hydrolyzate of the formula (I) in which X is -C (O) -O- and R 'is - (CH ₂ ) ₁₇ -CH ₃ stands. Use according to one of claims 1 to 6, characterized in that the cationic keratin hydrolyzate is a cationic keratin hydrolyzate with the INCI name Cocodimonium Hydroxypropyl Hydrolyzed Keratin. Use according to one of claims 1 to 7, characterized in that the hair treatment agent additionally - based on its weight - 0.01 to 10 wt .-%, preferably 0.05 to 7 wt .-%, particularly preferably 0.1 to 5 Wt .-%, more preferably 0.25 to 2.5 wt .-% and in particular 0.5 to 2.0 wt .-% protein hydrolyzate (s), preferably keratin hydrolyzate (s).